China Reform Health Management and Services Group Co Ltd

Nearly 100 stocks were surveyed by institutions over the past week. Among them, Guoxin Health received surveys from 139 institutions, including 31 securities firms, 47 private funds, and 10 insurance companies, making it the most surveyed stock. During the survey, Guoxin Health said the rapid revenue growth in its health services business in the first half was mainly driven by continued progress in chronic disease management and health management operations, with chronic disease management business in Shandong continuing to advance. Regarding the national healthcare security administration's personal medical insurance cloud initiative, on July 30, 2026, the Big Data Center of the National Healthcare Security Administration publicly confirmed that Guoxin Health will lead the effort, together with the China Academy of Information and Communications Technology, to undertake the preparation of the implementation plan for the personal medical insurance cloud scenario, and phased progress has already been made. Fushine Pharmaceutical expects net profit attributable to the parent company for the first three quarters of 2026 to be between 350 million yuan and 430 million yuan, up 658% to 785% year on year. Third-quarter net profit attributable to the parent company is expected to rise 50% to 119% from the second quarter, mainly because sales volume and prices of new energy lithium battery electrolyte additive products increased together, driving a sharp improvement in performance and a turnaround from loss to profit. Bojay Electronics saw first-half net profit attributable to the parent company grow more than sevenfold year on year, and new orders in the big data and AI computing power segment in the first half of 2026 rose nearly 350% year on year. Huabao Flavours and Fragrances has seen its share price rise sharply recently. In a survey, the company said this was affected by multiple factors, including improved first-half performance, increased research into core flavour raw materials for new tobacco products such as heat-not-burn and oral nicotine pouches and entry into the supply chains of leading global tobacco customers, sector valuations at historical lows, and a certain degree of increase in sugar prices. In terms of market performance, stocks surveyed by institutions over the past week rose by an average of 0.27%, with Huning Elevator, Entive Smart Kitchen, and Changlan Electric Technology among the top gainers.

Today, the pharmaceutical sector in the A-share market was active, with the DRG/DIP sub-sector leading gains. ST Rongke hit the 20 percent daily limit up, while Inspur Software, Saili Medical, and Guoxin Health also reached their daily limit up. In terms of news, the National Administration of Traditional Chinese Medicine and 10 other departments jointly issued the Action Plan for the Traditional Chinese Medicine Component of the Medical and Health Foundation Strengthening Project, aiming to enhance the supply of traditional Chinese medicine services at the grassroots level. About one minute after the afternoon session opened, Guoxin Health surged straight to its daily limit up, with its stock price reaching 7.17 yuan per share and its latest market capitalization at 7.021 billion yuan. Guoxin Health primarily engages in comprehensive medical insurance management services, offering DRG, DIP, and other diversified payment method services to medical insurance clients, and leveraging AI technology to provide solutions for medical institutions and disease control departments.